HERZ心脏
HERZ(英文缩写 HERZ),ISSN 0340-9937,eISSN 1615-6692,中文译名:心脏 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 1.740 | Q4 |
| 2022 | 1.700 | Q4 |
| 2023 | 1.100 | Q4 |
| 2024 | 0.900 | Q4 |
| 2025 | 1.600 | Q3 |
HERZ 最新收录文献
-
1. [Atrial fibrillation : An overview of the various treatment options].
PMID:日期:2026-09-24Atrial fibrillation is associated with a reduced quality of life, an increased risk of thromboembolic events and higher mortality. A fast and individualized treatment is essential, particularly to positively influence the progression. In addition to risk-adapted oral anticoagulation, early rhythm control is crucial for reducing the burden of symptoms as well as for decreasing hospitalization, ischemic stroke and cardiovascular death. Options for rhythm control include pharmacological strategies, electrical cardioversion, and catheter-based ablation procedures. Electrical cardioversion is particularly suitable for the acute treatment of hemodynamically unstable patients, while pharmacological treatment and catheter ablation represent long-term treatment approaches. Class IC antiarrhythmic drugs such as flecainide and propafenone are contraindicated in patients with structural heart disease.
-
2. Colchicine attenuates myocardial inflammation, endothelial dysfunction, and apoptosis in a rat model of alcohol-related cardiac damage.
PMID:日期:2026-09-03Chronic alcohol consumption is a recognized contributor to non-ischemic dilated cardiomyopathy, particularly in individuals with an underlying genetic predisposition, through myocardial inflammation, oxidative stress, and apoptosis. Colchicine, an NLRP3 inflammasome inhibitor, has cardioprotective potential, but its role in alcohol-induced injury is unknown. This study aimed to evaluate the dose-dependent effects of colchicine (0.1 mg/kg and 0.3 mg/kg) on alcohol-induced cardiac damage in rats. Overall, 40 Sprague-Dawley rats were randomized into five groups: control, alcohol (20% ethanol, 2.5 g/kg i.p.), colchicine alone, alcohol + standard-dose colchicine, and alcohol + high-dose colchicine. After 28 days, blood, cardiac, and liver tissues were analyzed for oxidative stress, inflammation, vascular injury, and apoptosis markers, along with histopathology. Alcohol exposure significantly increased oxidative stress, inflammatory (interleukin-1β, tumor necrosis factor α, high-sensitivity C‑reactive protein), vascular injury, and apoptotic markers (all p < 0.001). Colchicine attenuated these elevations dose-dependently, with the high dose (0.3 mg/kg) providing significantly greater protection across nearly all parameters (p < 0.001). Histopathology confirmed that colchicine reduced alcohol-induced cardiomyocyte hypertrophy and inflammatory infiltration. Colchicine exerts dose-dependent cardioprotective effects against alcohol-induced injury by mitigating inflammation, oxidative stress, and apoptosis. High-dose colchicine offers superior protection, suggesting its potential therapeutic role in alcohol-related cardiac damage.
-
3. Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".
PMID:日期:2026-09-03Low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). ESC/EAS guidelines recommend reducing LDL-C < 1.4 mmol/L and > 50% from baseline in patients with myocardial infarction. "Jena auf Ziel" (JaZ) is a prospective cohort study in which early combination therapy with atorvastatin 80 mg and ezetimibe 10 mg was initiated on admission in patients with ST-elevation myocardial infarction (STEMI) to reduce LDL‑C levels early and effectively. In this secondary analysis, we included 42 patients who were naïve to lipid-lowering therapy (LLT) on admission. Aim of the current analysis was to assess individual variations in LDL‑C response and to investigate the associations between plasma surrogate markers of cholesterol metabolism at baseline and LDL‑C reductions after 4-6 weeks on combined LLT. Combined LLT with atorvastatin 80 mg and ezetimibe 10 mg reduced LDL‑C after 6 weeks in all patients very effectively (47.7-92.5%) across all quartiles of cholesterol absorption and synthesis markers. No statistically significant differences in LDL‑C reduction were observed across quartiles of cholesterol metabolism markers, although Pearson correlation analysis indicated a modest association between sitosterol:cholesterol and LDL‑C response. The median LDL‑C reduction was > 60% in all quartiles of cholesterol absorption (sitosterol:cholesterol, campesterol:cholesterol, cholestanol:cholesterol) and synthesis markers (lathosterol:cholesterol). We found no statistically significant differences regarding the LDL‑C change from baseline (%) in quartiles of sitosterol:cholesterol, campesterol:cholesterol, cholestanol:cholesterol (markers of cholesterol absorption), and lathosterol:cholesterol (marker of cholesterol synthesis). However, Pearson correlation values indicated a correlation between sitosterol:cholesterol and LDL‑C reduction with higher ratios being associated with less pronounced LDL‑C reduction. Upfront dual therapy with atorvastatin (80 mg) and ezetimibe (10 mg) achieved robust LDL‑C reduction with low interindividual variability in treatment-naive individuals. We found no significant association between baseline cholesterol metabolism markers and treatment response. This supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metabolic phenotype.
-
4. [Management of elevated blood pressure and hypertension : Focus on risk reduction].
4. [高血压和高血压的管理：注重降低风险]PMID:日期:2026-08-01The 2024 hypertension guidelines from the European Society of Cardiology (ESC) introduce the category of 'elevated blood pressure' (120-139/70-89 mm Hg) and emphasise the importance of early prevention in individuals with such blood pressure levels and comorbid conditions. As blood pressure is recognised as a continuous risk factor, early initiation of antihypertensive treatment may be recommended even below the hypertensive range, depending on overall cardiovascular risk. All affected individuals should adopt a healthy lifestyle: regular exercise, balanced diet, reduced alcohol and salt intake, weight loss, and smoking cessation. If blood pressure remains > 130/80 mm Hg after three months and the patient has cardiovascular disease, heart failure, or a moderate to high risk, pharmacotherapy is advised. At ≥ 140/90 mm Hg, lifestyle measures and low-dose dual combination therapy should be initiated concurrently. The target systolic blood pressure is 120-129 mm Hg, with exceptions for individuals with frailty or those aged > 85 years. For resistant hypertension, spironolactone is the recommended pharmacological therapy, while renal denervation is listed as an interventional option.
-
5. [Advancing cardiovascular prevention : Evidence-based design of healthy and sustainable food environments].
PMID:日期:2026-08-01Malnutrition is among the leading modifiable risk factors for cardiovascular diseases worldwide. Current international guidelines consistently recommend predominantly plant-based dietary patterns rich in vegetables, fruits, whole grains, legumes and unsaturated fats. At the same time, the diet affects not only individual health but also the ecological foundations of future health. The nutrition system substantially contributes to greenhouse gas emissions, biodiversity loss, land-use change and freshwater consumption. This article argues that nutrition should therefore be understood as a dual lever for prevention: both for reducing cardiovascular disease and for stabilizing health-relevant ecological systems. While evidence supporting the cardiovascular benefits of high-quality plant-based diets continues to grow, implementation at the population level remains insufficient. The article discusses the limited long-term effectiveness of purely educational and individual responsibility-focused approaches and contrasts these with the more consistent evidence supporting structural interventions. In particular, fiscal policies, restrictions on unhealthy food marketing, healthy food standards in public institutions and modifications of food environments have demonstrated robust effects on dietary behavior and health outcomes. Against this background an expansion of cardiovascular prevention towards the active shaping of healthy and sustainable food environments is proposed. Physicians and medical societies could play a substantially stronger role in advocating evidence-based structural prevention policies.
-
6. [Effects of air pollution on cardiovascular health].
PMID:日期:2026-08-01Ambient air pollution is a leading modifiable environmental determinant of cardiovascular morbidity and mortality worldwide. Long-term and short-term exposure to fine particulate matter and traffic-related pollutants is consistently associated with an increased risk of ischemic heart disease, stroke, heart failure, arrhythmia and cardiovascular death. Mechanistic studies demonstrate that inhaled pollutants induce pulmonary and systemic oxidative stress, inflammation, endothelial dysfunction, autonomic imbalance and prothrombotic changes, providing biological plausibility for these associations. Air pollution rarely acts in isolation but clusters with other environmental stressors, such as transportation noise, heat and limited access to green space and disproportionately affects socioeconomically disadvantaged and medically vulnerable groups. This review summarizes the current evidence on the cardiovascular effects of air pollution, highlights high-risk populations and discusses clinical, public health and policy strategies to reduce exposure and vulnerability. We argue that contemporary cardiovascular prevention must adopt an exposome-oriented perspective and engage with transport, energy, housing and urban planning policies to effectively protect vulnerable patients and communities.
-
7. [Heart and climate].
7. [心脏和气候]PMID:日期:2026-08-01Temperature changes affect cardiovascular health through multiple physiological and environmental pathways. Cold exposure activates the sympathetic nervous system and the renin-angiotensin-aldosterone system, increases blood pressure, cardiac afterload and myocardial oxygen demand and can thereby promote ischemia, angina pectoris and myocardial infarction. In contrast, exposure to heat causes vasodilation, fluid loss through sweating, tachycardia and a rise in myocardial oxygen demand; dehydration, inflammation and prothrombotic changes can further increase the risk of acute cardiovascular events and renal dysfunction. Epidemiological data consistently show a U-shaped association between ambient temperature and cardiovascular mortality, with older adults and patients with pre-existing cardiovascular disease being particularly vulnerable. Air pollution, especially fine particulate matter, ozone and nitrogen dioxide can amplify heat-related risks. Beyond the immediate effects of temperature extremes, long-term adaptation leads to a shift in the minimum mortality temperature toward warmer conditions, while climate change increases exposure to heat waves and warm nights. We summarize the underlying pathophysiological mechanisms, clinical consequences and the growing relevance of temperature-related cardiovascular risks for public health. Effective climate adaptation, reduction of urban heat islands, promotion of low-emission transport and health-oriented urban planning are essential components in the prevention of temperature-associated morbidity and mortality.
-
8. Bleeding risk associated with the co-use of direct oral anticoagulants and non-dihydropyridine calcium channel blockers: a meta-analysis.
8. 与直接口服抗凝剂和非二氢吡啶类钙通道阻滞剂联合使用相关的出血风险：荟萃分析PMID:日期:2026-08-01Oral anticoagulation is a cornerstone of stroke prevention in patients with atrial fibrillation (AF) and elevated thromboembolic risk. However, evidence regarding the association between co-use of direct oral anticoagulants (DOACs) and non-dihydropyridine calcium-channel blockers (CCBs) and bleeding risk remains controversial. We systematically searched PubMed, Embase, and the Cochrane Library for randomized clinical trials, cohort, and case-control studies evaluating bleeding risk associated with DOAC + CCB co-use in patients with AF. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for binary outcomes. Nine studies met inclusion criteria, comprising 408,276 patients overall, of whom 67,359 were using DOACs + CCBs. Meta-analysis showed a significantly higher incidence of major bleeding with DOAC + CCB co-use compared with DOAC alone (OR 1.21 [95% CI 1.18-1.43]; p < 0.001; I = 21%). By contrast, there was no significant difference in any bleeding events between groups (OR 1.21 [95% CI 0.83-1.77]; p = 0.31; I = 77%). Co-use of DOACs and non-dihydropyridine CCBs is associated with an increased risk of major bleeding, whereas the overall risk of any bleeding does not differ significantly. Large randomized controlled trials are warranted to confirm these findings and to further evaluate the safety of this combination.
-
9. Clinical applications of artificial intelligence in hypertension management: current evidence and future perspectives.
PMID:日期:2026-07-17Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, with persistently inadequate blood pressure control despite guideline-directed therapy. The rapid expansion of digital health data and computational capacity has positioned artificial intelligence (AI) as a promising tool for improving hypertension management through enhanced risk prediction, phenotyping, and individualized care. However, important challenges related to external validation, interpretability, implementation, and real-world clinical benefit remain unresolved. We conducted a structured narrative review with a systematic literature search across PubMed/MEDLINE, Embase, and Scopus for studies published between January 2015 and December 2025. Eligible studies evaluated clinically relevant applications of AI in hypertension, including screening, diagnosis, cardiovascular risk stratification, treatment optimization, clinical decision support, and remote monitoring. Findings were synthesized qualitatively because of substantial heterogeneity in study design, AI methodology, and reported outcomes. AI-based models demonstrated favorable performance in predicting incident hypertension and cardiovascular risk using electronic health records, wearable technologies, and multimodal clinical datasets. Machine learning approaches frequently outperformed conventional risk prediction models, with reported area under the curve values generally ranging from approximately 0.75 to 0.90 across representative studies. AI-supported systems also showed potential for personalized antihypertensive therapy, resistant hypertension identification, and continuous blood pressure monitoring. However, most available evidence remains based on retrospective or internally validated datasets, and relatively few studies have demonstrated robust external validation or improvements in hard clinical outcomes such as cardiovascular events or mortality. Major barriers to implementation include data heterogeneity, algorithmic bias, limited interpretability, insufficient external validation, infrastructure and cost requirements, regulatory uncertainty, and concerns regarding patient trust and data privacy. In addition, evidence supporting widespread clinical implementation remains limited by the scarcity of large prospective randomized trials. AI has the potential to substantially transform hypertension management by enabling more precise, proactive, and personalized care. Nevertheless, rigorous prospective validation, improved transparency, equitable implementation strategies, and seamless integration into clinical workflows will be essential before widespread clinical adoption can be achieved.
-
10. Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.
PMID:日期:2026-06-24Psychological distress is common among patients with cardiovascular disease. While European Society of Cardiology (ESC) position papers highlight the relevance of mental health in cardiology care, psychosocial assessment remains inconsistently implemented in routine clinical practice. In this preliminary cross-sectional survey, patients attending a tertiary cardiology department completed an anonymous multidimensional psychosocial screening during routine care. Standardized instruments assessed depressive symptoms (PHQ-9), generalized anxiety (GAD-7), heart-focused anxiety (HAF-17), sleep disturbances (Jenkins Sleep Scale), resilient coping (BRCS), loneliness (UCLA-3), life satisfaction, perceived stress, social support, medication adherence, and awareness of psychocardiology services. A total of 62 patients were included. Overall levels of depressive and generalized anxiety symptoms were low (PHQ‑9 5.0 ± 4.7; GAD‑7 3.5 ± 4.4), while heart-focused anxiety was more pronounced (HAF-17 21.1 ± 10.6). Perceived stress was reported by 52.1% of participants (43.8% mild, 8.3% severe), and sleep disturbances were frequent (JSS 6.5 ± 5.5). Heart-focused anxiety showed consistent associations with general anxiety, depressive symptoms, stress, and sleep problems (all p < 0.05), but was not related to life satisfaction (p = 0.99). Life satisfaction correlated more strongly with general emotional well-being than with cardiac-specific fears. Despite limited prior awareness of psychocardiology services (7.0% aware), a substantial proportion of patients reported interest in receiving psychosocial support in a cardiology setting (8.8% yes and 47.4% maybe). Psychosocial burden in cardiology patients may extend beyond depression and generalized anxiety. Cardiac-specific fears, stress, and sleep disturbances are prominent but frequently underrecognized domains that may be overlooked by unidimensional screening approaches. A significant proportion of patients were unaware of existing psychocardiology services, suggesting a gap between recommended mental health integration and routine cardiology care. Multidimensional screening may facilitate more targeted identification of patients who could benefit from integrated psychocardiological care.